Back to Research Home
TMOThermo Fisher Scientific Inc
Health Care · Life Sciences Tools & Services · Mega
$673.82−0.40%
As of 23 Oct 2026Mkt cap $225B
Stage 13
AVOID
Fundamentals
40.0/75
Technical
4.9/15
Independent
44.9/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −0.7%
- 3M
- +20.4%
- 6M
- +43.5%
- 1Y
- +18.8%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 36.3xHist median 30.9x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 34.8x
- FCF yield
- 2.9%
Quality
- ROIC
- 9.0%
- Operating margin
- 17.1%
- FCF margin
- 14.1%
- Current ratio
- 1.9x
Growth
- Revenue growth
- +3.9%Latest FY YoY
- Revenue CAGR
- +3.2%
- EPS CAGR
- −2.3%
- FCF CAGR
- −1.9%
Capital
- Share-count trend
- −1.3%3Y annualised
- Net debt
- $29.6B3.8x OCF
Annual trend
- CAGR 2021–2025
- +3.2%
- Latest · 2025
- $45B
- YoY
- +3.9%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2027-01-28
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded